AZD6918 + gemcitabine

AZD6918 + gemcitabine is a **combination of AZD6918, a small molecule Trk (tropomyosin receptor kinase) inhibitor, and gemcitabine, a nucleoside analog antineoplastic agent**. AZD6918 is an oral, potent and selective inhibitor mainly targeting the Trk tyrosine kinases, including TrkA (encoded by the NTRK1 gene), which are implicated in tumorigenesis and drug resistance in certain solid malignancies, particularly neuroblastoma. Gemcitabine is a cytotoxic chemotherapeutic agent that inhibits DNA synthesis, primarily used in the treatment of various solid tumors such as pancreatic, lung, and breast cancer. The combination was studied in early-phase clinical trials to assess safety, tolerability, and pharmacokinetics, with a focus on whether the addition of AZD6918 would enhance the cytotoxic effect of gemcitabine in advanced or refractory solid tumors. The clinical development of this combination did not progress beyond early-phase trials.